Search

Your search keyword '"Buisseret L"' showing total 148 results

Search Constraints

Start Over You searched for: Author "Buisseret L" Remove constraint Author: "Buisseret L" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
148 results on '"Buisseret L"'

Search Results

3. 179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort

5. 176P Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study

11. 59P Tumor cells-adipocytes interactions are associated with poor disease outcome in invasive lobular carcinoma

12. 34P Investigating morphological heterogeneity in luminal breast cancer integrating artificial intelligence and spatial transcriptomics

13. 224P Immune characterization of de novo metastatic breast cancer

14. LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

15. LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)

19. 98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase

21. Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

22. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

23. Impact of HIV infection on baseline characteristics and survival of women with breast cancer: a systematic review and meta-analysis

24. O03.3 Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial

25. 72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast

26. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

29. 84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial

30. 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

32. 188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis

33. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

34. First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

35. SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

36. Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort

37. Abstract PD5-09: Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up

39. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer

40. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer

41. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer

42. Abstract PD6-05: Distinct tumor microenvironments stratify triple negative breast cancer into immune subtypes

43. Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

44. Immune Infiltration in Invasive Lobular Breast Cancer

50. Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients

Catalog

Books, media, physical & digital resources